Mallinckrodt Teams with Zydus

Published Online: Friday, April 1, 2005

Mallinckrodt Pharmaceuticals Generics has entered into a strategic alliance with Zydus Cadila's US subsidiary, Zydus Pharmaceuticals Inc. The agreement calls for Mallinckrodt Pharmaceuticals Generics to market and sell products under a shared Mallinckrodt-Zypharma label. The products will be developed and registered by Zydus Pharmaceuticals and will be manufactured by Zydus Cadila at its US FDA-approved manufacturing plant in Ahmedabad, India.

By melding Mallinckrodt's marketing and distribution networks with Zydus Cadila's product development and manufacturing success, Mallinckrodt expands its product portfolio and pipeline.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues